Success Metrics

Clinical Success Rate

100.0%

Based on 4 completed trials

Completion Rate

100%(4/4)

Active Trials

2(33%)

Results Posted

75%(3 trials)

Phase Distribution

Ph phase_1

17%

Ph phase_3

33%

Ph phase_2

50%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Phase 1Safety & dosage

1(16.7%)

Phase 2Efficacy & side effects

3(50.0%)

Phase 3Large-scale testing

2(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(2)

Completed(4)

Detailed Status

Completed4

Active, not recruiting2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 3

Trials by Phase

Phase 11 (16.7%)

Phase 23 (50.0%)

Phase 32 (33.3%)

Trials by Status

completed467%

active_not_recruiting233%

Recent Activity

2 active trials

Showing 5 of 6

active_not_recruitingphase_2

Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma

NCT01808599

active_not_recruitingphase_1

Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

NCT02180711

completedphase_2

A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)

NCT04660799

completedphase_3

Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT)

NCT02303119

completedphase_2

Intrathecal Rituximab in Progressive Multiple Sclerosis

NCT02545959

View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials

NCT01808599Phase 2

Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma

Active Not Recruiting

NCT02180711Phase 1

Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

Active Not Recruiting

NCT04660799Phase 2

A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Completed

NCT02303119Phase 3

Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT)

Completed

NCT02545959Phase 2

Intrathecal Rituximab in Progressive Multiple Sclerosis

Completed

NCT01200758Phase 3

A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma

Completed

All 6 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 6